Pakistan accuses pharmaceutical companies of malpractice

The Federal Board of Revenue (FBR) in Pakistan believes pharmaceutical companies have used transfer pricing to evade Rp500 million ($5.8 million) in taxes.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: